Dr. Y. Lynn Wang, MD, PhD
Pathologist | Clinical Pathology
333 Cottman Ave Philadelphia PA, 19111About
Dr. Y. Lynn Wang, a board-certified molecular pathologist, is specialized in the development and interpretation of molecular and genomic clinical assays including PCR, RT-PCR, FISH, Sanger sequencing and Next-gen sequencing assays. She served as the Founding Director of the Genomic and Molecular Pathology Division at the University of Chicago and Director of Molecular Hematopathology at Weill Cornell Medical College before she joined Fox Chase Cancer Center in 2018. She contributed >75 publications to the medical and scientific literature. Many of them are well cited including the report in the New England Journal of Medicine and one of the top-cited articles in Leukemia. Dr. Wang is an inventor on two issued US patents.
Education and Training
Beijing Medical University MD 1988
University of Pennsylvania Residency 2002
Board Certification
Molecular Genetic Pathology (Pathology)
Provider Details
Faculty Titles & Positions
- Medical Director of Molecular Pathology Fox Chase Cancer Center 2021 - Present
- Professor Fox Chase Cancer Center 2018 - Present
Awards
- Top cited article “Functional characterization of BTKC481S mutation…” 2015 Leukemia
- Top cite article “BTK inhibition targets in vivo CLL proliferation…” 2014 Leukemia
- Best Lymphoma Abstract 2021 Lymphoma Leukemia & Myeloma Congress 2021
Professional Memberships
- College of American Pathologists
- American Society of Hematology
- Association for Molecular Pathology
Treatments
- Diagnosis
Fellowships
- Hospital of the University of Pennsylvania
Professional Society Memberships
- 1996-presentAssociation for Molecular Pathology2006-presentAmerican Society for Investigative Pathology2007-presentAmerican Society of Hematology2008-presentElected Fellow, College of American Pathologists2010-presentUnited States and Canadian Academy of Pathology2022-presentAsian American Academy of Science and Engineering
Teaching and speaking
- Dr. Y. Lynn Wang has delivered >75 seminar nationally and internationally
Hobbies / Sports
- Photography
Favorite professional publications
- Blood Leukemia
Areas of research
As a physician-scientist, Dr. Wang is the principal investigator of several translational research projects on aberrant signal transduction pathways in B-cell lymphoma and leukemia.
1. Targeting B-cell receptor signaling (BCR) in lymphoid malignancies.
2. Mechanisms of resistance to BCR-targeted therapies.
3. Strategies to overcome BCR resistance via blocking of other signaling pathways.
4. Applications of new therapeutic models in lymphoma and CLL to the investigation of drug resistance
Dr. Y. Lynn Wang, MD, PhD's Practice location
Dr. Y. Lynn Wang, MD, PhD's reviews
Write ReviewMedia Releases
Get to know Pathologist Dr. Y. Lynn Wang, who serves cancer patients in Philadelphia, Pennsylvania.
Dr. Wang, a board-certified molecular pathologist, is specialized in the development and interpretation of molecular and genomic clinical assays including PCR, RT-PCR, FISH, Sanger sequencing, microsatellite analyses and Next-gen sequencing assays.
Since 2021, she has been serving as the Medical Director of Molecular Pathology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She holds a rank of full Professor within the Department of Pathology and Blood Cell Development and Function Program at Fox Chase Cancer Center since 2018.
As a principal investigator & physician-scientist, Dr. Wang leads several translational research projects on aberrant signal transduction pathways in B-cell lymphoma and leukemia. She is an expert on cell signaling and sensitivity/resistance to targeted therapies.
Her lab works on molecular-targeted therapies in CLL and non-Hodgkin lymphoma with emphasis on: B-cell receptor signaling in non-Hodgkin lymphoma and CLL, mechanisms of sensitivity and resistance to targeted therapies in non-Hodgkin lymphoma, rational drug combination in non-Hodgkin lymphoma, and ex vivo models.
Prior to joining Fox Chase Cancer Center, she served as the Founding Director of the Genomic and Molecular Pathology Division and the Director of Lymphoma Translational Pathology at the University of Chicago from 2013 to 2018, and as the Director of Molecular Hematopathology at Weill Cornell Medical College from 2002 to 2013.
Dr. Wang graduated with her medical degree from Beijing Medical University in China in 1988. She then relocated to the United States, earned her PhD in molecular biology/biochemistry at Brandeis University in 1995, and her fellowship in molecular pathology within the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Medical Center in 1997.
Furthering her training, she performed her residency in clinical pathology within the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Medical Center in 2002, her postdoctoral research in cancer biology at Abramson Family Cancer Research Institute in 2002, and her medical degree at the University of the State of New York, also in 2002.
Subsequent to her education, Dr. Wang attained board certifications in molecular genetic pathology & clinical pathology through the American Board of Pathology. Its mission is to serve the public and advance the profession of pathology by setting certification standards and promoting lifelong competency of pathologists.
Remaining up to date in her field, she is an active member of the American Society of Hematology, the Association for Molecular Pathology, the College of American Pathologists (Fellow), the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology.
Pathology is a branch of medical science that involves the study and diagnosis of disease through the examination of surgically removed organs, tissues, bodily fluids, and in some cases, the whole body. Pathologists are physicians who specialize in the diagnosis and management can help your primary care doctors make a diagnosis about your medical condition.
A well accomplished investigator, Dr. Wang has made 75 contributions to peer-reviewed medical and scientific literature. Her work on B-cell receptor signaling and ibrutinib resistance have appeared in journals such as New England Journal of Medicine, Blood, Leukemia, JAMA Oncology, British Journal of Hematology, Oncogene, Blood Advances, and many others. She has presented her laboratory findings at numerous national and international meetings and her work is widely cited by her peers. Dr. Wang, in addition, is the inventor on two patents related to resistance to BTK inhibitor ibrutinib.
Among her various accolades include the Yao Yuan Award for Research Excellence (2017) & Travel Award, American Society for Clinical Investigation (2006, 2008).
On a more personal note, Dr. Wang’s hobbies include photography and outdoor activities such as skiing and kayaking. She speaks both English and Chinese.
Recommended Articles
- What Occurs During The Different Stages of Prostate Cancer?
What Occurs During The Different Stages of Prostate Cancer?Prostate cancer is an infection of the prostate which causes abnormal growth of cells on the prostate gland. Prostate cancer is known to inhabit the body of an individual for a long time before displaying any symptoms. During the first...
- Anti-Inflammatory Diet Plan and Food List
The Immune SystemThe human body's immune system does an excellent job taking care of our health, as it is made of chemicals, cells, and biological systems that work together to protect us. The immune system recognizes foreign substances like viruses and bacteria easily, and works to stop their...
- Hypertension: When Should I Call a Doctor?
Emergency situations with high blood pressure, called hypertensive crisis, are common when blood pressure is very high. This is a serious situation, as it may lead to organ damage. If the increase in blood pressure is not too high to cause any problems to any of the organs it is referred to as...
- Risk of Kidney Deterioration Low in MS Patients, Study Suggests
Multiple sclerosis (MS) damages the nerves that send signals to the muscles, thereby making it much more difficult to control them. The nerves connected to the bladder are no exception. ...
- AstraZeneca Gains United States Approval for Lymphoma Drug
Some forms of lymphoma are rarer than others. Most people can recognize Hodgkin lymphoma, but mantle cell lymphoma will strike them as a surprise.Because it is so rare, there are not as many drugs specific to this form of cancer. One has recently been approved in the United States, by the Food and...
- How Chief Nursing Staff Should Use the Four Pillars of Patient Experience
Nursing is known to be one of the most challenging professions that requires a certain amount of passion in order to help a patient recover properly. ...
Nearby Providers
- Dr. Karen Gustafson MD333 Cottman Ave Philadelphia PA 19111
- Dr. Douglas Brian Flieder M.D.333 Cottman Avenue Philadelphia PA 19111
- Dr. Yue-lynn Wang M.D.333 COTTMAN AVE PHILADELPHIA PA 19111
- Dr. Harry Cooper M.D.333 Cottman Ave Philadelphia PA 19111
- Dr. Min Huang M.D.333 Cottman Ave Philadelphia PA 19111
- Dr. Nancy A Young M.D.333 Cottman Ave Philadelphia PA 19111